Inagaki-Ohara Kyoko, Kondo Taisuke, Ito Minako, Yoshimura Akihiko
Department of Gastroenterology; Research Center for Hepatitis and Immunology; Research Institute; National Center for Global Health and Medicine (NCGM); Ichikawa, Japan.
JAKSTAT. 2013 Jul 1;2(3):e24053. doi: 10.4161/jkst.24053. Epub 2013 Aug 15.
Signal transduction pathways elicited by cytokines and hormones have been shown to regulate distinct stages of development. Suppressor of cytokine signaling (SOCS) proteins are negative feedback regulators of cytokine signaling mediated by the JAK-STAT signaling pathway. In particular, SOCS1 and SOCS3 are potent inhibitors of JAKs and can play pivotal roles in inflammation, as well as in the development and progression of cancers. Abnormal expression of SOCS1 and SOCS3 in cancer cells has been reported in human carcinoma associated with dysregulation of signals from cytokine receptors, Toll-like receptors (TLRs), and hormone receptors, resulting in malignancies. In this review, we focus on the role of SOCS1 and SOCS3 in cancer development. In addition, the potential of SOCS as a therapeutic target and diagnostic aid will be discussed.
细胞因子和激素引发的信号转导通路已被证明可调节不同的发育阶段。细胞因子信号转导抑制因子(SOCS)蛋白是由JAK-STAT信号通路介导的细胞因子信号的负反馈调节因子。特别是,SOCS1和SOCS3是JAKs的有效抑制剂,可在炎症以及癌症的发生和发展中发挥关键作用。据报道,在与细胞因子受体、Toll样受体(TLR)和激素受体信号失调相关的人类癌症中,癌细胞中SOCS1和SOCS3表达异常,从而导致恶性肿瘤。在本综述中,我们重点关注SOCS1和SOCS3在癌症发展中的作用。此外,还将讨论SOCS作为治疗靶点和诊断辅助手段的潜力。